Search for drugs:
Typing the drug name to query
TENOFOVIR ALAFENAMIDE
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Cardiac Electrophysiology
- In a thorough QT/QTc study in 48 healthy subjects, tenofovir alafenamide at the recommended dose or at a dose 5 times the recommended dose did not affect the QT/QTc interval and did not prolong the PR interval.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
1
24091
Other ADRs
1920
38379667
Odds Ratio = 0.83
Drug Property Information
ATC Code(s):
- J05AF13 - tenofovir alafenamide
- J05AF1 -
- J05AF - Nucleoside and nucleotide reverse transcriptase inhibitors
- J05A - DIRECT ACTING ANTIVIRALS
- J05 - ANTIVIRALS FOR SYSTEMIC USE
- J - ANTIINFECTIVES FOR SYSTEMIC USE
Active Ingredient:TENOFOVIR ALAFENAMIDE FUMARATE
Active Ingredient UNII:FWF6Q91TZO
Drugbank ID:DB14126
PubChem Compound:N/ADIR Classification
CTD ID:C442442
PharmGKB:PA10204
CAS Number:147127-20-6
Dosage Form(s):tablet
Route(s) Of Administrator:oral
Daily Dose:
- 25.0 mg/day J05AF13
Chemical Structure: 
SMILE Code:
C[C@H](CN1C=NC2=C1N=CN=C2N)OCP(O)(O)=O
C[C@H](CN1C=NC2=C1N=CN=C2N)OCP(O)(O)=O
Reference
N/A
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.